Submitted by dcc on Thu, 2017-02-16 13:44 Study Title: Phase 2 Trial of XL184 (Cabozantinib); an Oral Small-Molecule Inhibitor of Multiple Kinases; in Children and Young Adults with Refractory Sarcomas; Wilms Tumor; and Other Rare TumorsCIRB: Pediatric CIRBLead Group: COGStatus: ActiveReview Status: Available to Open
